Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator

Donna P. Ankerst(The University of Texas at San Antonio Health Science Center), Michael A. Liss(University of San Diego), Martin Goros(The University of Texas at San Antonio Health Science Center), Ziding Feng(The University of Texas MD Anderson Cancer Center), Dattatraya Patil(Emory University), Scott A. Tomlins(Stratasys (Israel)), Robin J. Leach(The University of Texas at San Antonio Health Science Center), Martin G. Sanda(Emory University), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), John T. Wei(University of Michigan), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
European Urology Focus
February 13, 2018
10.1016/j.euf.2018.01.010
Cited by 24

Related Papers

Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
|Cell|1993|2.3k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k